10:27 AM EDT, 04/29/2025 (MT Newswires) -- AstraZeneca ( AZN ) halted its phase 3 trial for prostate cancer treatment Truqap based on the recommendation of an independent data monitoring committee.

The trial, which evaluated the efficacy and safety of Truqap in combination with docetaxel and androgen-deprivation therapy in patients with metastatic castration-resistant prostate cancer, was deemed unlikely to achieve the primary endpoints of radiographic progression-free survival and overall survival versus the comparator arm, AstraZeneca ( AZN ) said Tuesday in a statement, citing the committee's recommendation.

Price: 70.59, Change: +0.66, Percent Change: +0.94